Drug intelligence / Profile preview

interferon alpha-14

Development stage
Preclinical
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration
Intramuscular, Subcutaneous
01

Overview

Interferon alpha-14 (IFN-α14) is a specific subtype of the Type I interferon family, a group of cytokines essential for the innate immune response against viral infections and malignancies. Encoded by the *IFNA14* gene, this protein signals through the heterodimeric Type I interferon receptor (IFNAR), composed of IFNAR1 and IFNAR2 subunits. Binding to this receptor activates the JAK-STAT signaling pathway, leading to the nuclear translocation of transcription factors that induce the expression of hundreds of interferon-stimulated genes (ISGs). IFN-α14 is distinguished by its high biological potency; research has demonstrated that it possesses significantly greater antiviral activity against HIV-1 compared to the more commonly utilized IFN-α2 subtype, effectively inhibiting viral replication and inducing potent restriction factors in various cell types. While not currently marketed as a standalone recombinant pharmaceutical product, it is a naturally occurring constituent of multi-subtype human leukocyte interferon preparations, such as Multiferon, which are used therapeutically for viral and neoplastic conditions.

Other names
Interferon alpha-14IFN-alpha-14IFN-alpha14IFN-alpha 14IFN-α14Interferon alpha H
02

Targets

IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)

Beyond the preview

Go deeper on interferon alpha-14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon alpha-14.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call